Probiotic Efficacy Evaluation Service in GI Disorder Models

We primarily use well-characterized mouse and rat models because their genetics, immune responses, sampling options, and established GI disease protocols support controlled comparative studies. When a project requires larger-animal physiology, we can discuss model suitability and available collaborative options, including porcine studies where appropriate.

Yes. We can help translate the intended product profile and mechanism into a preclinical study strategy, recommend model and endpoint combinations, and organize methods and results into a traceable data package. The scope supports scientific and IND-enabling planning but does not replace formal legal or regulatory advice.

The final report describes the model, groups, dosing, sample schedule, methods, quality observations, statistical analyses, results, and an integrated interpretation. High-resolution figures and tables are included, and applicable raw files, sequencing outputs, histology images, and recorded measurements are supplied in agreed formats.

Selection begins with the intended indication, mechanism, preventive or therapeutic use, expected duration, and most important decision endpoint. DSS is useful for epithelial injury and acute or chronic colitis, TNBS emphasizes cell-mediated inflammation, genetic models support chronic disease questions, and IBS models focus on motility, sensitivity, and functional outcomes.

Often yes, provided sample volumes, collection timing, group size, and tissue allocation are planned together. We build a sampling map before study initiation so fecal strain tracking, permeability, cytokines, histology, sequencing, and metabolites can be compared without compromising the primary efficacy endpoint.